Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo shows promise for endometrial, ovarian cancers

Key clinical point: Daily lenvatinib plus weekly paclitaxel was considered active and well tolerated in a phase 1 trial of patients with recurrent endometrial or ovarian cancer.

Major finding: The combination produced an objective response rate of 65%, and most adverse events were grade 1 or 2.

Study details: Phase 1 trial of 26 patients.

Disclosures: This investigator-initiated study was supported by Eisai. The speaker disclosed relationships with Eisai, ImmunoGen, Clovis Oncology, Tesaro, Merck, and Agenus.


Backes FJ et al. SGO 2019, Abstract LBA5.